Interleukin Inhibitors Market

Interleukin Inhibitors Market by Applications (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, and Others), Types (IL-17, IL-23, IL-1, IL-5, IL-6, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-1267
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 186
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global interleukin inhibitors market size is anticipated to expand at a substantial CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing prevalence of autoimmune diseases and growing adoption of interleukin inhibitors.
 

Interleukin Inhibitors Market Key Takjeaways


Interleukin (IL) is a group of cytokines which are synthesized by macrophages, monocytes, lymphocytes, and other cells. Interleukin regulate cell motility, cell growth, and cell differentiation. Inside the body there are total fifteen different types of interleukin are present. Interleukin inhibitors are immunosuppressive agents which prevent the action of interleukins. IL inhibitors are used in many conditions such as arthritis (psoriatic and rheumatoid), ankylosing spondylitis, systematic sclerosis, gout, psoriasis, asthma, and eczema.

There is a substantial paradigm shift in the autoimmune diseases treatment over the last few decades. The inclination toward targeted therapies is increasing because of improvement in safety and efficiency of profiles. Patent expiry and raised acceptance of biosimilar in Tumor Necrosis Factor (TNF) inhibitors has increased the market growth. Launching of new products are aided the market growth. For instance, AbbVie, Inc., in 2019, launched Skyrizi (risankizumab-rzaa) for plaque psoriasis treatment. Also, in 2018, Ilumya (tildrakizumab-asmn) was launched by Sun Pharmaceutical Industries Inc. for moderate-to-severe plaque psoriasis.

Due to upcoming launches of late-stage pipeline candidates the demand of interleukin inhibitors is increasing. Expansion of labels of marketed products, for example, Dupixent for atopic dermatitis and Actemra for juvenile idiopathic arthritis are estimated to boost the penetration. Also, ongoing clinical trials are helping IL inhibitors market with their positive outcomes.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing awareness about benefits of interleukin inhibitors among physicians and consumers is major factor responsible for the market expansion during the forecast period.
  • Increasing favorable initiatives and programs by government for promoting usage of interleukin inhibitors and accessibility to strong pipeline of products are projected to drive the market growth.
  • Rising prevalence of autoimmune disorders and other inflammatory diseases and rising number of investigational drugs are anticipated to fuel the growth of the market.
  • Increasing FDA approvals for therapies and novel drugs for treatment of chronic inflammatory disease is expected to propel the market growth in coming years.
  • Growing presence of targeted therapies because of its efficiency and safety is estimated to drive the market growth during the forecast period.
  • High cost of utilization and adoption of treatment in different disease application is major factor that can hamper the market growth.
  • Strict regulations and guidelines, and side effects related to this treatment are projected to impede the market growth over the forecast period.

Scope of the Report

The report on the global interleukin inhibitors market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Interleukin Inhibitors Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Applications (Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Asthma, Inflammatory Bowel Disease, and Others), Types (IL-17, IL-23, IL-1, IL-5, IL-6, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Johnson & Johnson Services, Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., and Teva Pharmaceuticals Industries, Ltd.

Market Segment Insights

Psoriasis segment is projected to hold a major market share

Based on applications, the interleukin inhibitors market is divided into psoriasis, psoriatic arthritis, rheumatoid arthritis, asthma, inflammatory bowel disease, and others. The psoriasis segment is expected to hold a key share of the market during the forecast period due to strong performances of Stelara, Cosentyx, and Taltz. Favorable reimbursement policies, growing prevalence of diseases, and increasing awareness among consumers are expected to fuel the segment growth.

On the other hand, the psoriatic arthritis segment is anticipated to expand at a rapid pace during the forecast period. Due to upcoming launches of late-stage pipeline products and expansion of labels of existing products specified for Crohn’s disease, ulcerative colitis, and arthritis are major factors responsible for the market growth.
 

Interleukin Inhibitors Market by applications

IL-17 segment is expected to grow at a rapid pace

On the basis of types, the interleukin inhibitors market is segmented into IL-17, IL-23, IL-1, IL-5, IL-6, and others. The IL-23 segment dominated the market share and is expected to account for a key share of the market in the coming years due to new entrants and usage of blockbuster drug Stelara. Also, there are other drugs which are added, such as Tremfya in 2017, Ilumya in 2018, and Skyrizi in 2019. Still Stelara is generating largest revenue in spite of its patent expiry in 2023.

However, the IL-17 segment is anticipated to expand at a rapid pace during the forecast period owing to increase in sales of Cosentyx and Taltz. In 2017, a third year of launch, Cosentyx became a blockbuster drug. Launch of Siliq and awaiting approval of bimekizumab are projected to drive the segment growth.

 North America is expected to dominate the market

On the basis of regions, the interleukin inhibitors market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to dominate the market during the forecast period. The regional market growth can be attributed to increasing commercial sales of interleukin inhibitors in the U.S. In addition to this, there are some other factors responsible for the regional growth are rise in expenditure of healthcare, local presence of major market players, and favorable government initiatives.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years owing to economic development, rise in disposable income, growing awareness among consumers, and improvement in infrastructure of healthcare. Developing countries including India, China, and South Korea are projected to boost the segment growth.
 

Interleukin Inhibitors Market by Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Interleukin Inhibitors Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Interleukin Inhibitors Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Interleukin Inhibitors Market - Supply Chain
  4.5. Global Interleukin Inhibitors Market Forecast
     4.5.1. Interleukin Inhibitors Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Interleukin Inhibitors Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Interleukin Inhibitors Market Absolute $ Opportunity
5. Global Interleukin Inhibitors Market Analysis and Forecast by Types
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Types
     5.2.2. Y-o-Y Growth Projections by Types
  5.3. Interleukin Inhibitors Market Size and Volume Forecast by Types
     5.3.1. IL-17
     5.3.2. IL-23
     5.3.3. IL-1
     5.3.4. IL-5
     5.3.5. IL-6
     5.3.6.
  5.4. Absolute $ Opportunity Assessment by Types
  5.5. Market Attractiveness/Growth Potential Analysis by Types
6. Global Interleukin Inhibitors Market Analysis and Forecast by Applications
  6.1. Market Trends
  6.2. Introduction
     6.2.1. Basis Point Share (BPS) Analysis by Applications
     6.2.2. Y-o-Y Growth Projections by Applications
  6.3. Interleukin Inhibitors Market Size and Volume Forecast by Applications
     6.3.1. Psoriasis
     6.3.2. Psoriatic Arthritis
     6.3.3. Rheumatoid Arthritis
     6.3.4. Asthma
     6.3.5. Inflammatory Bowel Disease (IBD)
     6.3.6.
  6.4. Absolute $ Opportunity Assessment by Applications
  6.5. Market Attractiveness/Growth Potential Analysis by Applications
7. Global Interleukin Inhibitors Market Analysis and Forecast by Region
  7.1. Market Trends
  7.2. Introduction
     7.2.1. Basis Point Share (BPS) Analysis by Region
     7.2.2. Y-o-Y Growth Projections by Region
  7.3. Interleukin Inhibitors Market Size and Volume Forecast by Region
     7.3.1. North America
     7.3.2. Latin America
     7.3.3. Europe
     7.3.4. Asia Pacific
     7.3.5. Middle East and Africa (MEA)
  7.4. Absolute $ Opportunity Assessment by Region
  7.5. Market Attractiveness/Growth Potential Analysis by Region
  7.6. Global Interleukin Inhibitors Demand Share Forecast, 2019-2026
8. North America Interleukin Inhibitors Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
  8.2. North America Interleukin Inhibitors Market Size and Volume Forecast by Country
     8.2.1. U.S.
     8.2.2. Canada
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. North America Interleukin Inhibitors Market Size and Volume Forecast by Types
     8.4.1. IL-17
     8.4.2. IL-23
     8.4.3. IL-1
     8.4.4. IL-5
     8.4.5. IL-6
     8.4.6.
  8.5. Basis Point Share (BPS) Analysis by Types
  8.6. Y-o-Y Growth Projections by Types
  8.7. North America Interleukin Inhibitors Market Size and Volume Forecast by Applications
     8.7.1. Psoriasis
     8.7.2. Psoriatic Arthritis
     8.7.3. Rheumatoid Arthritis
     8.7.4. Asthma
     8.7.5. Inflammatory Bowel Disease (IBD)
     8.7.6.
  8.8. Basis Point Share (BPS) Analysis by Applications
  8.9. Y-o-Y Growth Projections by Applications
  8.10. Market Attractiveness/Growth Potential Analysis
     8.10.1. By Country
     8.10.2. By Product Type
     8.10.3. By Application
  8.11. North America Interleukin Inhibitors Demand Share Forecast, 2019-2026
9. Latin America Interleukin Inhibitors Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Latin America Average Pricing Analysis
  9.2. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Country
      9.2.1. Brazil
      9.2.2. Mexico
      9.2.3. Rest of Latin America
   9.3. Absolute $ Opportunity Assessment by Country
  9.4. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Types
     9.4.1. IL-17
     9.4.2. IL-23
     9.4.3. IL-1
     9.4.4. IL-5
     9.4.5. IL-6
     9.4.6.
  9.5. Basis Point Share (BPS) Analysis by Types
  9.6. Y-o-Y Growth Projections by Types
  9.7. Latin America Interleukin Inhibitors Market Size and Volume Forecast by Applications
     9.7.1. Psoriasis
     9.7.2. Psoriatic Arthritis
     9.7.3. Rheumatoid Arthritis
     9.7.4. Asthma
     9.7.5. Inflammatory Bowel Disease (IBD)
     9.7.6.
  9.8. Basis Point Share (BPS) Analysis by Applications
  9.9. Y-o-Y Growth Projections by Applications
  9.10. Market Attractiveness/Growth Potential Analysis
     9.10.1. By Country
     9.10.2. By Product Type
     9.10.3. By Application
  9.11. Latin America Interleukin Inhibitors Demand Share Forecast, 2019-2026
10. Europe Interleukin Inhibitors Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Europe Average Pricing Analysis
  10.2. Europe Interleukin Inhibitors Market Size and Volume Forecast by Country
     10.2.1. Germany
     10.2.2. France
     10.2.3. Italy
     10.2.4. U.K.
     10.2.5. Spain
     10.2.6. Russia
     10.2.7. Rest of Europe
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Europe Interleukin Inhibitors Market Size and Volume Forecast by Types
     10.4.1. IL-17
     10.4.2. IL-23
     10.4.3. IL-1
     10.4.4. IL-5
     10.4.5. IL-6
     10.4.6.
  10.5. Basis Point Share (BPS) Analysis by Types
  10.6. Y-o-Y Growth Projections by Types
  10.7. Europe Interleukin Inhibitors Market Size and Volume Forecast by Applications
     10.7.1. Psoriasis
     10.7.2. Psoriatic Arthritis
     10.7.3. Rheumatoid Arthritis
     10.7.4. Asthma
     10.7.5. Inflammatory Bowel Disease (IBD)
     10.7.6.
  10.8. Basis Point Share (BPS) Analysis by Applications
  10.9. Y-o-Y Growth Projections by Applications
  10.10. Market Attractiveness/Growth Potential Analysis
     10.10.1. By Country
     10.10.2. By Product Type
     10.10.3. By Application
  10.11. Europe Interleukin Inhibitors Demand Share Forecast, 2019-2026
11. Asia Pacific Interleukin Inhibitors Market Analysis and Forecast
  11.1. Introduction
     11.1.1. Basis Point Share (BPS) Analysis by Country
     11.1.2. Y-o-Y Growth Projections by Country
     11.1.3. Asia Pacific Average Pricing Analysis
  11.2. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Country
     11.2.1. China
     11.2.2. Japan
     11.2.3. South Korea
     11.2.4. India
     11.2.5. Australia
     11.2.6. Rest of Asia Pacific (APAC)
  11.3. Absolute $ Opportunity Assessment by Country
  11.4. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Types
     11.4.1. IL-17
     11.4.2. IL-23
     11.4.3. IL-1
     11.4.4. IL-5
     11.4.5. IL-6
     11.4.6.
  11.5. Basis Point Share (BPS) Analysis by Types
  11.6. Y-o-Y Growth Projections by Types
  11.7. Asia Pacific Interleukin Inhibitors Market Size and Volume Forecast by Applications
     11.7.1. Psoriasis
     11.7.2. Psoriatic Arthritis
     11.7.3. Rheumatoid Arthritis
     11.7.4. Asthma
     11.7.5. Inflammatory Bowel Disease (IBD)
     11.7.6.
  11.8. Basis Point Share (BPS) Analysis by Applications
  11.9. Y-o-Y Growth Projections by Applications
  11.10. Market Attractiveness/Growth Potential Analysis
     11.10.1. By Country
     11.10.2. By Product Type
     11.10.3. By Application
  11.11. Asia Pacific Interleukin Inhibitors Demand Share Forecast, 2019-2026
12. Middle East & Africa Interleukin Inhibitors Market Analysis and Forecast
  12.1. Introduction
     12.1.1. Basis Point Share (BPS) Analysis by Country
     12.1.2. Y-o-Y Growth Projections by Country
     12.1.3. Middle East & Africa Average Pricing Analysis
  12.2. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Country
     12.2.1. Saudi Arabia
     12.2.2. South Africa
     12.2.3. UAE
     12.2.4. Rest of Middle East & Africa (MEA)
  12.3. Absolute $ Opportunity Assessment by Country
  12.4. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Types
     12.4.1. IL-17
     12.4.2. IL-23
     12.4.3. IL-1
     12.4.4. IL-5
     12.4.5. IL-6
     12.4.6.
  12.5. Basis Point Share (BPS) Analysis by Types
  12.6. Y-o-Y Growth Projections by Types
  12.7. Middle East & Africa Interleukin Inhibitors Market Size and Volume Forecast by Applications
     12.7.1. Psoriasis
     12.7.2. Psoriatic Arthritis
     12.7.3. Rheumatoid Arthritis
     12.7.4. Asthma
     12.7.5. Inflammatory Bowel Disease (IBD)
     12.7.6.
  12.8. Basis Point Share (BPS) Analysis by Applications
  12.9. Y-o-Y Growth Projections by Applications
  12.10. Market Attractiveness/Growth Potential Analysis
     12.10.1. By Country
     12.10.2. By Product Type
     12.10.3. By Application
  12.11. Middle East & Africa Interleukin Inhibitors Demand Share Forecast, 2019-2026
13. Competition Landscape
  13.1. Global Interleukin Inhibitors Market: Market Share Analysis
  13.2. Interleukin Inhibitors Distributors and Customers
  13.3. Interleukin Inhibitors Market: Competitive Dashboard
  13.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     13.4.1. Johnson & Johnson Services, Inc.
     13.4.2. Novartis AG
     13.4.3. AbbVie Inc.
     13.4.4. Eli Lilly and Company
     13.4.5. Regeneron Pharmaceuticals, Inc.
     13.4.6. AstraZeneca
     13.4.7. Bausch Health
     13.4.8. F. Hoffmann-La Roche Ltd.
     13.4.9. GlaxoSmithKline plc.
     13.4.10. Teva Pharmaceuticals Industries, Ltd.&l

Segments Covered in the Report
The global interleukin inhibitors market has been segmented on the basis of

Applications

  • Psoriasis
  • Psoriatic Arthritis
  • Rheumatoid Arthritis
  • Asthma
  • Inflammatory Bowel Disease (IBD)
  • Others

Types

  • IL-17
  • IL-23
  • IL-1
  • IL-5
  • IL-6
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson Services, Inc.
  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals, Inc.
  • AstraZeneca
  • Bausch Health
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc.
  • Teva Pharmaceuticals Industries, Ltd.

Key players competing in the interleukin inhibitors market include Johnson & Johnson Services, Inc., Novartis AG, AbbVie Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc., AstraZeneca, Bausch Health, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc., and Teva Pharmaceuticals Industries, Ltd.

Major market players are focusing on several business strategies including mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to enhance their market shares. For instance, Eli Lilly and Company is involved in the development of Mirikizumab which is an IL-23 product. It is under phase 3 trial and specified for ulcerative colitis and psoriasis.
 

Interleukin Inhibitors Market by key Players

Buy Report